• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » WuXi Cuts U.S. Manufacturing Business

WuXi Cuts U.S. Manufacturing Business

December 3, 2008
CenterWatch Staff

Chinese contract research organization (CRO) WuXi PharmaTech is discontinuing its U.S. biologics manufacturing operations as of December 31. As a result, the company will cut about 100 manufacturing and supporting positions at its Philadelphia facility.

“Given the depressed demand and the high cost structure of our biologics manufacturing services, we will focus on expanding our biologics testing, cell banking and cell therapy services in our Philadelphia site instead,” said WuXi CFO Benson Tsang in an investor conference call yesterday.

WuXi acquired the Philadelphia manufacturing operations as part of its January 2008 acquisition of AppTec, a U.S.-based laboratory services provider. Although company executives were initially optimistic about the potential for U.S.-based manufacturing, year-end 2008 forecasts have biologics manufacturing revenues at less than 4% of total expected annual revenue.

A company executive said in Tuesday’s call that the biologics manufacturing business is relatively risky, and when the economy takes a downturn, biotech companies just don’t have the financing for it. He said WuXi doesn’t see a turnaround in the foreseeable future.

The CRO will begin cutting manufacturing operations this month to be completed by early spring 2009. The restructuring will cost the company between $2.5 million and $3.5 million in the next few months, according to Tsang, but it will result in an annual cost-savings of approximately $10 million.

The discontinuation of U.S.-based biologics manufacturing does not eliminate WuXi from the manufacturing business altogether. Tsang told investors Tuesday that the company would begin to test run a large-scale manufacturing facility in China by the end of this year, with plans to provide commercial Active Pharmaceutical Ingredients manufacturing services in 2009.

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing